Aditya Bagrodia

I love it before. And I can think back to the early days when I was just starting and kind of knew that germ cell testis was going to be my primary area of interest. And the SEMS trial was just kind of getting going. And I reached out to SIA. We opened it there. And I was literally so thrilled to put four patients on. And that did give me some validity within my own kind of institution, region.

kind of got things going. So I think it's super sound advice, whether it's multi-institutional IITs, co-op group trials, get out there, see what is exciting to you, interesting to you, and then you knock it out of the park. And maybe I'll just also add, I think in the spirit of always improving, don't be intimidated. It doesn't need to be, like you said, a grand slam from the get-go.

kind of got things going. So I think it's super sound advice, whether it's multi-institutional IITs, co-op group trials, get out there, see what is exciting to you, interesting to you, and then you knock it out of the park. And maybe I'll just also add, I think in the spirit of always improving, don't be intimidated. It doesn't need to be, like you said, a grand slam from the get-go.

kind of got things going. So I think it's super sound advice, whether it's multi-institutional IITs, co-op group trials, get out there, see what is exciting to you, interesting to you, and then you knock it out of the park. And maybe I'll just also add, I think in the spirit of always improving, don't be intimidated. It doesn't need to be, like you said, a grand slam from the get-go.

It could be a QI project that you're like, huh, that seems compelling. I would like to disseminate this. And then you can look at different mechanisms. Well, before, you know, thanks. I knew it was going to be a thoughtful, reflective conversation on other things that have worked well and some of the pitfalls as well. So I appreciate your time.

It could be a QI project that you're like, huh, that seems compelling. I would like to disseminate this. And then you can look at different mechanisms. Well, before, you know, thanks. I knew it was going to be a thoughtful, reflective conversation on other things that have worked well and some of the pitfalls as well. So I appreciate your time.

It could be a QI project that you're like, huh, that seems compelling. I would like to disseminate this. And then you can look at different mechanisms. Well, before, you know, thanks. I knew it was going to be a thoughtful, reflective conversation on other things that have worked well and some of the pitfalls as well. So I appreciate your time.

Great to see you again and look forward to connecting soon.

Great to see you again and look forward to connecting soon.

Great to see you again and look forward to connecting soon.

Our audio team is led by Kieran Gannon, with support from Josh McWhirter, Aaron Bowles, Josh Spencer.

Our audio team is led by Kieran Gannon, with support from Josh McWhirter, Aaron Bowles, Josh Spencer.

Our audio team is led by Kieran Gannon, with support from Josh McWhirter, Aaron Bowles, Josh Spencer.

This week on the Backtable Podcast.

This week on the Backtable Podcast.

This week on the Backtable Podcast.

Hello, everyone, and welcome back to the Backtable podcast, your source for all things urology. You can find all previous episodes of our podcast on Apple, Spotify, and at backtable.com. Now, a quick word from our sponsor. This discussion is brought to you by VeriCyte, provider of the Decipher Prostate Genomic Classifier.

Hello, everyone, and welcome back to the Backtable podcast, your source for all things urology. You can find all previous episodes of our podcast on Apple, Spotify, and at backtable.com. Now, a quick word from our sponsor. This discussion is brought to you by VeriCyte, provider of the Decipher Prostate Genomic Classifier.

Hello, everyone, and welcome back to the Backtable podcast, your source for all things urology. You can find all previous episodes of our podcast on Apple, Spotify, and at backtable.com. Now, a quick word from our sponsor. This discussion is brought to you by VeriCyte, provider of the Decipher Prostate Genomic Classifier.

Decipher Prostate is a test for patients with localized prostate cancer that can help personalize treatment. Every patient and their prostate cancer is unique, and Decipher Prostate can provide meaningful insight into the aggressiveness of each individual patient's tumor.